Nuvation Bio Inc. financial data

Symbol
NUVB, NUVB-WT on NYSE
Industry
Pharmaceutical Preparations
Location
357 Tehama Street, Floor 3, San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Panacea Acquisition Corp (to 2/11/2021)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24K % -72.5%
Debt-to-equity 12.5 % +354%
Return On Equity -125 % -923%
Return On Assets -97.9 % -724%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 337M shares +53.7%
Common Stock, Shares, Outstanding 338M shares +54.2%
Entity Public Float 523B USD +100%
Common Stock, Value, Issued 1.37B USD +45%
Weighted Average Number of Shares Outstanding, Basic 269K shares +22.8%
Weighted Average Number of Shares Outstanding, Diluted 269K shares +22.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 727K USD
Research and Development Expense 99.1M USD +39%
General and Administrative Expense 28.2M USD -12.5%
Operating Income (Loss) -593M USD -494%
Nonoperating Income (Expense) 24.7M USD +2.78%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -568M USD -649%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -568M USD -649%
Earnings Per Share, Basic -2.11 USD/shares -503%
Earnings Per Share, Diluted -2.11 USD/shares -503%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.7M USD -16.2%
Marketable Securities, Current 467M USD -17.9%
Assets, Current 526M USD -14.6%
Property, Plant and Equipment, Net 586K USD -18.3%
Operating Lease, Right-of-Use Asset 2.4M USD -33.4%
Other Assets, Noncurrent 6.62M USD +1027%
Assets 541M USD -13%
Accounts Payable, Current 6.35M USD +187%
Accrued Liabilities, Current 32.8M USD +235%
Contract with Customer, Liability, Current 11.1M USD
Liabilities, Current 58.2M USD +317%
Contract with Customer, Liability, Noncurrent 15.6M USD
Accrued Income Taxes, Noncurrent 679K USD +372%
Operating Lease, Liability, Noncurrent 969K USD -52.4%
Liabilities 76.8M USD +370%
Common Stocks, Including Additional Paid in Capital 117M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 573K USD +217%
Retained Earnings (Accumulated Deficit) -911M USD -166%
Stockholders' Equity Attributable to Parent 464M USD -23.4%
Liabilities and Equity 541M USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.7M USD +18.8%
Net Cash Provided by (Used in) Financing Activities 21K USD -93%
Net Cash Provided by (Used in) Investing Activities 7.54M USD
Common Stock, Shares, Issued 338M shares +54.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.14M USD +88.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.7M USD -16.2%
Deferred Tax Assets, Valuation Allowance 238M USD +137%
Deferred Tax Assets, Gross 243M USD +139%
Operating Lease, Liability 2.63M USD -34.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -568M USD -710%
Lessee, Operating Lease, Liability, to be Paid 2.78M USD -35.4%
Property, Plant and Equipment, Gross 1.46M USD +5.57%
Operating Lease, Liability, Current 1.66M USD -15.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 837K USD -40.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.77M USD -18.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 143K USD -50.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 171K USD -72.8%
Deferred Tax Assets, Operating Loss Carryforwards 108M USD +268%
Unrecognized Tax Benefits 7.39M USD +31.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 144K USD -77.1%
Share-based Payment Arrangement, Expense 32.3M USD +65.4%
Interest Expense 132K USD